Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Srinivasan Website

Ramaprasad Srinivasan, M.D., Ph.D.

Selected Publications

1)  Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metwalli AR, Srinivasan R, Linehan WM.
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.
J. Clin. Oncol. 32: 431-7, 2014.
2)  Shuch B, Linehan WM, Srinivasan R.
Aerobic glycolysis: a novel target in kidney cancer.
Expert Rev Anticancer Ther. 13: 711-9, 2013.
3)  Liu NW, Sanford T, Srinivasan R, Liu JL, Khurana K, Aprelikova O, Valero V, Bechert C, Worrell R, Pinto PA, Yang Y, Merino M, Linehan WM, Bratslavsky G.
Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma.
Clin. Cancer Res. 19: 42-9, 2013.
4)  Linehan WM, Srinivasan R, Garcia JA.
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.
Semin. Oncol. 40: 511-20, 2013.
5)  Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, Ross R, Eisenberg P, Meltzer PS, Merino MJ, Bottaro DP, Linehan WM, Srinivasan R.
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
J. Clin. Oncol. 31: 181-6, 2013.
6)  Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ.
Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation.
Am. J. Surg. Pathol. 37: 368-74, 2013.
7)  Linehan WM, Srinivasan R.
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep.
Nat Rev Clin Oncol. 10: 614-5, 2013.
8)  Shuch B, Bratslavsky G, Linehan WM, Srinivasan R.
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.
Oncologist. 17: 46-54, 2012.
9)  Ricketts CJ, Shuch B, Vocke CD, Metwalli AR, Bratslavsky G, Middelton L, Yang Y, Wei MH, Pautler SE, Peterson J, Stolle CA, Zbar B, Merino MJ, Schmidt LS, Pinto PA, Srinivasan R, Pacak K, Linehan WM.
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer.
J. Urol. 188: 2063-71, 2012.
10)  Shuch B, Vourganti S, Friend JC, Zehngebot LM, Linehan WM, Srinivasan R.
Targeting the mTOR pathway in Chromophobe Kidney Cancer.
J Cancer. 3: 152-7, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 4/15/2014.